Condition
Myasthenia Gravis Generalised
Total Trials
5
Recruiting
1
Active
2
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
20%
1 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
1Total
P 3 (1)
Trial Status
Not Yet Recruiting2
Active Not Recruiting1
Completed1
Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT07033559Not Yet RecruitingPrimary
Detecting Fatigue From Voice in Generalised Myasthenia Gravis
NCT07337395Not Yet RecruitingPrimary
Proteomic Changes in Patients With Myasthenia Gravis and Ravulizumab
NCT06906692Active Not RecruitingPrimary
Meningococcal Vaccination in Patients on Complement Inhibitors
NCT06617741Recruiting
Myasthenia Gravis Foundation of America Global MG Patient Registry
NCT00408213Phase 3CompletedPrimary
A Continuation Study to Assess the Effect of CellCept in Patients With Myasthenia Gravis.
Showing all 5 trials